When analyzing the mutation rates of KRAS, NRAS, and BRAF in different locations, it can be found that KRAS gene mutation rate was significantly different in colon cancers (44.2%), rectal cancers (37.1%) and gastric cancers (0%) (p < 0.001). This evidence concerns the gene NRAS and malignant colon neoplasm.